| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
|
Am J Respir Crit Care Med
|
2012
|
22.96
|
|
2
|
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
|
N Engl J Med
|
2007
|
19.86
|
|
3
|
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
|
Am J Respir Crit Care Med
|
2008
|
6.17
|
|
4
|
Chronic obstructive pulmonary disease phenotypes: the future of COPD.
|
Am J Respir Crit Care Med
|
2010
|
4.19
|
|
5
|
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.
|
Lancet Respir Med
|
2012
|
3.98
|
|
6
|
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations.
|
Am J Respir Crit Care Med
|
2012
|
3.09
|
|
7
|
Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.
|
J Am Coll Cardiol
|
2013
|
3.03
|
|
8
|
Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal.
|
Thorax
|
2010
|
2.86
|
|
9
|
Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire.
|
Chest
|
2007
|
2.67
|
|
10
|
Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study.
|
Circulation
|
2010
|
2.45
|
|
11
|
Withdrawal from treatment as an outcome in the ISOLDE study of COPD.
|
Chest
|
2003
|
2.44
|
|
12
|
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
|
Respir Res
|
2009
|
2.31
|
|
13
|
Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study.
|
Am J Respir Crit Care Med
|
2012
|
2.27
|
|
14
|
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.
|
Chest
|
2009
|
2.20
|
|
15
|
Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary.
|
Am J Respir Crit Care Med
|
2010
|
2.09
|
|
16
|
Variability of a closed, rebreathing setup for multiple breath wash-out testing in children.
|
Pediatr Pulmonol
|
2012
|
2.03
|
|
17
|
Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients.
|
Respiration
|
2012
|
1.99
|
|
18
|
Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival.
|
Heart Rhythm
|
2011
|
1.93
|
|
19
|
Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary?
|
J Am Coll Cardiol
|
2009
|
1.79
|
|
20
|
Real world evaluation of dual-zone ICD and CRT-D programming compared to single-zone programming: the ALTITUDE REDUCES study.
|
J Cardiovasc Electrophysiol
|
2011
|
1.69
|
|
21
|
The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trial.
|
Am J Respir Crit Care Med
|
2006
|
1.65
|
|
22
|
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.
|
Am J Respir Crit Care Med
|
2015
|
1.63
|
|
23
|
The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study.
|
Thorax
|
2011
|
1.54
|
|
24
|
The IBV Valve trial: a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema.
|
J Bronchology Interv Pulmonol
|
2014
|
1.51
|
|
25
|
Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.
|
Respir Res
|
2011
|
1.51
|
|
26
|
Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience.
|
Am J Respir Crit Care Med
|
2010
|
1.33
|
|
27
|
Cardiovascular events in patients with COPD: TORCH study results.
|
Thorax
|
2010
|
1.25
|
|
28
|
Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure.
|
Value Health
|
2010
|
1.21
|
|
29
|
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
|
BMC Pulm Med
|
2014
|
1.14
|
|
30
|
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
|
Respir Res
|
2010
|
1.14
|
|
31
|
Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire.
|
Thorax
|
2010
|
1.14
|
|
32
|
The severity of airways obstruction as a determinant of treatment response in COPD.
|
Int J Chron Obstruct Pulmon Dis
|
2006
|
1.11
|
|
33
|
Noise, artifact, and oversensing related inappropriate ICD shock evaluation: ALTITUDE noise study.
|
Pacing Clin Electrophysiol
|
2012
|
1.09
|
|
34
|
The COPD Assessment Test (CAT): short- and medium-term response to pulmonary rehabilitation.
|
COPD
|
2012
|
1.09
|
|
35
|
Multicentre European study for the treatment of advanced emphysema with bronchial valves.
|
Eur Respir J
|
2012
|
1.09
|
|
36
|
Analysis of comorbid factors that increase the COPD assessment test scores.
|
Respir Res
|
2014
|
1.06
|
|
37
|
Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations?
|
COPD
|
2012
|
1.06
|
|
38
|
Corticosteroid therapy in pulmonary sarcoidosis: a systematic review.
|
JAMA
|
2002
|
1.05
|
|
39
|
Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease.
|
Chest
|
2010
|
1.04
|
|
40
|
Derivation of normative data for the COPD assessment test (CAT).
|
Respir Res
|
2014
|
1.02
|
|
41
|
Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD.
|
Chest
|
2013
|
1.02
|
|
42
|
COPD and disease-specific health status in a working population.
|
Respir Res
|
2013
|
1.00
|
|
43
|
Validity of the COPD assessment test translated into local languages for Asian patients.
|
Chest
|
2013
|
0.94
|
|
44
|
Health-related quality of life in patients with chronic respiratory failure after long-term mechanical ventilation.
|
Respir Med
|
2005
|
0.94
|
|
45
|
Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease.
|
Int J Chron Obstruct Pulmon Dis
|
2011
|
0.93
|
|
46
|
Repeatability of a Rasch model of the AQ20 over five assessments.
|
Qual Life Res
|
2006
|
0.92
|
|
47
|
Prescribing patterns in premenstrual syndrome.
|
BMC Womens Health
|
2002
|
0.92
|
|
48
|
Measuring functional performance in patients with COPD: a discussion of patient-reported outcome measures.
|
Curr Med Res Opin
|
2007
|
0.88
|
|
49
|
Brazilian version of airways questionnaire 20: a reproducibility study and correlations in patients with COPD.
|
Respir Med
|
2004
|
0.87
|
|
50
|
Assessment of dyspnea in asthma: validation of The Dyspnea-12.
|
J Asthma
|
2011
|
0.86
|
|
51
|
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.
|
Ann Am Thorac Soc
|
2015
|
0.85
|
|
52
|
Comparison between an alternative and the classic definition of chronic bronchitis in COPDGene.
|
Ann Am Thorac Soc
|
2015
|
0.85
|
|
53
|
A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011.
|
Int J Chron Obstruct Pulmon Dis
|
2013
|
0.83
|
|
54
|
Impact of shock energy and ventricular rhythm on the success of first shock therapy: the ALTITUDE first shock study.
|
Heart Rhythm
|
2013
|
0.82
|
|
55
|
A critique of Rasch analysis using the Dyspnoea-12 as an illustrative example.
|
J Adv Nurs
|
2011
|
0.81
|
|
56
|
Evaluation of male COPD patients' health status by proxies.
|
Respir Med
|
2006
|
0.80
|
|
57
|
Phase II study of tight glycaemic control in COPD patients with exacerbations admitted to the acute medical unit.
|
BMJ Open
|
2011
|
0.79
|
|
58
|
GOLD COPD categories are not fit for purpose in primary care--authors' reply.
|
Lancet Respir Med
|
2013
|
0.79
|
|
59
|
COPD: functional status, health status and primary care.
|
Prim Care Respir J
|
2011
|
0.79
|
|
60
|
Impact of symptoms of anxiety and depression on COPD Assessment Test scores.
|
Eur Respir J
|
2013
|
0.79
|
|
61
|
A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations.
|
Eur Respir J
|
2012
|
0.78
|
|
62
|
Does change in device detected frequency of non-sustained or diverted episodes serve as a marker for inappropriate shock therapy? Analyses from the INTRINSIC RV and ALTITUDE-REDUCES Trials.
|
Europace
|
2014
|
0.78
|
|
63
|
Depression in chronic obstructive pulmonary disease: a common concomitant disease.
|
Am J Respir Crit Care Med
|
2011
|
0.77
|
|
64
|
Triple therapy for chronic obstructive pulmonary disease: trials catching up with clinical practice?
|
Am J Respir Crit Care Med
|
2009
|
0.77
|
|
65
|
Changes in thresholds for intracortical excitability in chronic stroke: more than just altered intracortical inhibition.
|
Restor Neurol Neurosci
|
2013
|
0.77
|
|
66
|
Implantable cardioverter defibrillator electrogram adjudication for device registries: methodology and observations from ALTITUDE.
|
Pacing Clin Electrophysiol
|
2011
|
0.76
|
|
67
|
Improvements in Lung Diffusion Capacity following Pulmonary Rehabilitation in COPD with and without Ventilation Inhomogeneity.
|
Respiration
|
2016
|
0.76
|
|
68
|
Adapting to asthma: are some asthma effects acceptable?
|
J Asthma
|
2006
|
0.76
|
|
69
|
Symptom measurement.
|
Chest
|
2008
|
0.75
|
|
70
|
Potential limitation of the COTE index in assessing the impact of comorbidities on mortality in chronic obstructive pulmonary disease.
|
Am J Respir Crit Care Med
|
2012
|
0.75
|
|
71
|
Performance of an automatic arrhythmia classification algorithm: comparison to the ALTITUDE electrophysiologist panel adjudications.
|
Pacing Clin Electrophysiol
|
2014
|
0.75
|
|
72
|
It's about time--directing our attention toward modifying the course of COPD.
|
Respir Med
|
2008
|
0.75
|